HLS Therapeutics Inc. (HLTRF)

Market Cap	98.74M +13.0%
Revenue (ttm)	55.50M -2.0%
Net Income	-12.43M
EPS	-0.39
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Average Volume	673
Open	3.000
Previous Close	n/a
Day's Range	3.000 - 3.000
52-Week Range	2.960 - 4.020
Beta	0.84
RSI	34.44
Earnings Date	Mar 12, 2026

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Craig Millian
• Employees: 85
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLTRF

Financial Performance

In 2025, HLS Therapeutics's revenue was $55.50 million, a decrease of -1.98% compared to the previous year's $56.62 million. Losses were -$12.43 million, -36.76% less than in 2024.